BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, Lipkin SM, Syngal S, Wollins DS, Lindor NM. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol. 2015;33:3660-3667. [PMID: 26324357 DOI: 10.1200/jco.2015.63.0996] [Cited by in Crossref: 324] [Cited by in F6Publishing: 123] [Article Influence: 54.0] [Reference Citation Analysis]
Number Citing Articles
1 Abdel-Razeq H, Al-Omari A, Zahran F, Arun B. Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer 2018;18:152. [PMID: 29409476 DOI: 10.1186/s12885-018-4079-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
2 Knerr S, Bowles EJA, Leppig KA, Buist DSM, Gao H, Wernli KJ. Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015. J Natl Cancer Inst 2019;111:795-802. [PMID: 30753636 DOI: 10.1093/jnci/djz008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
3 Conley CC, Ketcher D, Reblin M, Kasting ML, Cragun D, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST. The big reveal: Family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer. J Genet Couns 2020;29:410-22. [PMID: 31912597 DOI: 10.1002/jgc4.1196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
4 Luba DG, DiSario JA, Rock C, Saraiya D, Moyes K, Brown K, Rushton K, Ogara MM, Raphael M, Zimmerman D, Garrido K, Silguero E, Nelson J, Yurgelun MB, Kastrinos F, Wenstrup RJ, Syngal S. Community Practice Implementation of a Self-administered Version of PREMM1,2,6 to Assess Risk for Lynch Syndrome. Clin Gastroenterol Hepatol 2018;16:49-58. [PMID: 28668538 DOI: 10.1016/j.cgh.2017.06.038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
5 Kilbride MK, Domchek SM, Bradbury AR. Ethical Implications of Direct-to-Consumer Hereditary Cancer Tests. JAMA Oncol 2018;4:1327-8. [PMID: 30027223 DOI: 10.1001/jamaoncol.2018.2439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
6 Maani N, Panabaker K, McCuaig JM, Buckley K, Semotiuk K, Farncombe KM, Ainsworth P, Panchal S, Sadikovic B, Armel SR, Lin H, Kim RH. Incidental findings from cancer next generation sequencing panels. NPJ Genom Med 2021;6:63. [PMID: 34282142 DOI: 10.1038/s41525-021-00224-6] [Reference Citation Analysis]
7 Stenehjem DD, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, Stevens V, Brixner DI. Impact of a genetic counseling requirement prior to genetic testing. BMC Health Serv Res 2018;18:165. [PMID: 29514700 DOI: 10.1186/s12913-018-2957-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
8 Okur V, Chung WK. The impact of hereditary cancer gene panels on clinical care and lessons learned. Cold Spring Harb Mol Case Stud 2017;3:a002154. [PMID: 29162654 DOI: 10.1101/mcs.a002154] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
9 Clark DF, Maxwell KN, Powers J, Lieberman DB, Ebrahimzadeh J, Long JM, McKenna D, Shah P, Bradbury A, Morrissette JJD, Nathanson KL, Domchek SM. Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing. JCO Precis Oncol 2019;3. [PMID: 31511844 DOI: 10.1200/PO.19.00076] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Schäfer JF, Granata C, von Kalle T, Kyncl M, Littooij AS, Di Paolo PL, Sefic Pasic I, Nievelstein RAJ; Oncology Task Force of the ESPR. Whole-body magnetic resonance imaging in pediatric oncology - recommendations by the Oncology Task Force of the ESPR. Pediatr Radiol 2020;50:1162-74. [PMID: 32468287 DOI: 10.1007/s00247-020-04683-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
11 Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol 2017;35:1086-95. [PMID: 28135145 DOI: 10.1200/JCO.2016.71.0012] [Cited by in Crossref: 191] [Cited by in F6Publishing: 92] [Article Influence: 47.8] [Reference Citation Analysis]
12 Yadav S, Reeves A, Campian S, Paine A, Zakalik D. Outcomes of retesting BRCA negative patients using multigene panels. Fam Cancer 2017;16:319-28. [PMID: 27878467 DOI: 10.1007/s10689-016-9956-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
13 Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, Dotson WD, Bowen MS, Khoury MJ. Trends in utilization and costs of BRCA testing among women aged 18-64 years in the United States, 2003-2014. Genet Med 2018;20:428-34. [PMID: 28933789 DOI: 10.1038/gim.2017.118] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
14 Hallquist MLG, Tricou EP, Ormond KE, Savatt JM, Coughlin CR 2nd, Faucett WA, Hercher L, Levy HP, O'Daniel JM, Peay HL, Stosic M, Smith M, Uhlmann WR, Wand H, Wain KE, Buchanan AH. Application of a framework to guide genetic testing communication across clinical indications. Genome Med 2021;13:71. [PMID: 33926532 DOI: 10.1186/s13073-021-00887-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Bartley N, Napier C, Best M, Butow P. Patient experience of uncertainty in cancer genomics: a systematic review. Genet Med 2020;22:1450-60. [PMID: 32424175 DOI: 10.1038/s41436-020-0829-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Lynce F, Isaacs C. How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing. Am Soc Clin Oncol Educ Book 2016;35:e72-8. [PMID: 27249773 DOI: 10.1200/EDBK_160391] [Cited by in Crossref: 15] [Article Influence: 3.8] [Reference Citation Analysis]
17 Liang MI, Wong DH, Walsh CS, Farias-Eisner R, Cohen JG. Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers. J Genet Couns 2018;27:177-86. [PMID: 28785836 DOI: 10.1007/s10897-017-0135-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
18 Angeli D, Salvi S, Tedaldi G. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? Int J Mol Sci 2020;21:E1128. [PMID: 32046255 DOI: 10.3390/ijms21031128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
19 Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, McLeod MC, Jagsi R, Katz SJ. Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. J Clin Oncol 2017;35:2232-9. [PMID: 28402748 DOI: 10.1200/JCO.2016.71.6480] [Cited by in Crossref: 138] [Cited by in F6Publishing: 58] [Article Influence: 34.5] [Reference Citation Analysis]
20 Solano AR, Liria NC, Jalil FS, Faggionato DM, Mele PG, Mampel A, Cardoso FC, Podesta EJ. BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina. Front Oncol 2018;8:323. [PMID: 30186769 DOI: 10.3389/fonc.2018.00323] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
21 Kim ST, Kim KM, Kim NKD, Park JO, Ahn S, Yun JW, Kim KT, Park SH, Park PJ, Kim HC, Sohn TS, Choi DI, Cho JH, Heo JS, Kwon W, Lee H, Min BH, Hong SN, Park YS, Lim HY, Kang WK, Park WY, Lee J. Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. Oncologist 2017;22:1169-77. [PMID: 28701572 DOI: 10.1634/theoncologist.2017-0020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
22 Hume S, Nelson TN, Speevak M, McCready E, Agatep R, Feilotter H, Parboosingh J, Stavropoulos DJ, Taylor S, Stockley TL; Canadian College of Medical Geneticists (CCMG). CCMG practice guideline: laboratory guidelines for next-generation sequencing. J Med Genet 2019;56:792-800. [PMID: 31300550 DOI: 10.1136/jmedgenet-2019-106152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
23 Conway JR, Warner JL, Rubinstein WS, Miller RS. Next-Generation Sequencing and the Clinical Oncology Workflow: Data Challenges, Proposed Solutions, and a Call to Action. JCO Precis Oncol 2019;3:PO. [PMID: 32923847 DOI: 10.1200/PO.19.00232] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Meiser B, Quinn VF, Gleeson M, Kirk J, Tucker KM, Rahman B, Saunders C, Watts KJ, Peate M, Geelhoed E, Barlow-Stewart K, Field M, Harris M, Antill YC, Mitchell G. When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer. Eur J Hum Genet 2016;24:1517-23. [PMID: 27329735 DOI: 10.1038/ejhg.2016.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
25 Idos GE, Kurian AW, Ricker C, Sturgeon D, Culver JO, Kingham KE, Koff R, Chun NM, Rowe-Teeter C, Lebensohn AP, Levonian P, Lowstuter K, Partynski K, Hong C, Mills MA, Petrovchich I, Ma CS, Hartman AR, Allen B, Wenstrup RJ, Lancaster JM, Brown K, Kidd J, Evans B, Mukherjee B, McDonnell KJ, Ladabaum U, Ford JM, Gruber SB. Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precis Oncol 2019;3:PO. [PMID: 34322651 DOI: 10.1200/PO.18.00217] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Marron JM, Joffe S. Ethical considerations in genomic testing for hematologic disorders. Blood 2017;130:460-5. [PMID: 28600340 DOI: 10.1182/blood-2017-01-734558] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
27 Hamilton JG, Robson ME. Psychosocial Effects of Multigene Panel Testing in the Context of Cancer Genomics. Hastings Cent Rep 2019;49 Suppl 1:S44-52. [PMID: 31268573 DOI: 10.1002/hast.1016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
28 Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Morrow M, Berek JS, Hofer TP, Katz SJ. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. J Clin Oncol 2021;39:1631-40. [PMID: 33560870 DOI: 10.1200/JCO.20.02785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
29 Lee K, Seifert BA, Shimelis H, Ghosh R, Crowley SB, Carter NJ, Doonanco K, Foreman AK, Ritter DI, Jimenez S, Trapp M, Offit K, Plon SE, Couch FJ. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Genet Med 2019;21:1497-506. [PMID: 30504931 DOI: 10.1038/s41436-018-0361-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
30 Verdial FC, Bartek MA, Anderson BO, Javid SH. Genetic testing and surgical treatment after breast cancer diagnosis: Results from a national online cohort. J Surg Oncol 2021;123:1504-12. [PMID: 33735483 DOI: 10.1002/jso.26372] [Reference Citation Analysis]
31 Bradbury AR, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. J Natl Cancer Inst 2018;110:985-93. [PMID: 29490071 DOI: 10.1093/jnci/djy015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
32 Rotz SJ, Kodish E. Ethical conundrums in pediatric genomics. Hematology Am Soc Hematol Educ Program 2018;2018:301-6. [PMID: 30504324 DOI: 10.1182/asheducation-2018.1.301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Sie AS, Spruijt L, van Zelst-Stams WA, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB, Hoogerbrugge N. High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling. J Genet Couns 2016;25:504-14. [PMID: 26531312 DOI: 10.1007/s10897-015-9899-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
34 Castellanos E, Gel B, Rosas I, Tornero E, Santín S, Pluvinet R, Velasco J, Sumoy L, Del Valle J, Perucho M, Blanco I, Navarro M, Brunet J, Pineda M, Feliubadaló L, Capellá G, Lázaro C, Serra E. A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. Sci Rep 2017;7:39348. [PMID: 28051113 DOI: 10.1038/srep39348] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
35 Cardoso FC, Goncalves S, Mele PG, Liria NC, Sganga L, Diaz Perez I, Podesta EJ, Solano AR. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population. Hum Genomics 2018;12:39. [PMID: 30103829 DOI: 10.1186/s40246-018-0171-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
36 Wang YA, Jian JW, Hung CF, Peng HP, Yang CF, Cheng HS, Yang AS. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer 2018;18:315. [PMID: 29566657 DOI: 10.1186/s12885-018-4229-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
37 Mallen AR, Conley CC, Townsend MK, Wells A, Boac BM, Todd S, Gandhi A, Kuznicki M, Augusto BM, McIntyre M, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST. Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center. Clin Genet 2020;97:370-5. [PMID: 31600840 DOI: 10.1111/cge.13654] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE. BRCA testing and outcomes in women with breast cancer. Breast Cancer Res Treat 2021;186:839-50. [PMID: 33389410 DOI: 10.1007/s10549-020-06038-x] [Reference Citation Analysis]
39 Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw 2017;15:219-28. [PMID: 28188191 DOI: 10.6004/jnccn.2017.0022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
40 Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, O'Neil BB, Tward JD. Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO Precis Oncol 2021;5:PO. [PMID: 34250421 DOI: 10.1200/PO.20.00432] [Reference Citation Analysis]
41 Greenberg S, Slager S, Neil BO, Cooney K, Maughan B, Stopa N, Venne V, Zickmund S, Colonna S. What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. Prostate 2020;80:441-50. [PMID: 32027768 DOI: 10.1002/pros.23959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Kiryluk K, Goldstein DB, Rowe JW, Gharavi AG, Wapner R, Chung WK. Precision Medicine in Internal Medicine. Ann Intern Med 2019;170:635-42. [PMID: 31035290 DOI: 10.7326/M18-0425] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
43 Schultz CL, Alderfer MA, Lindell RB, McClain Z, Zelley K, Nichols KE, Ford CA. The Influence of Adolescence on Parents' Perspectives of Testing and Discussing Inherited Cancer Predisposition. J Genet Couns 2018. [PMID: 29909594 DOI: 10.1007/s10897-018-0267-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol 2018;36:414-24. [PMID: 29236593 DOI: 10.1200/JCO.2017.74.1173] [Cited by in Crossref: 93] [Cited by in F6Publishing: 34] [Article Influence: 23.3] [Reference Citation Analysis]
45 Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH. Additional germline findings from a tumor profiling program. BMC Med Genomics 2018;11:65. [PMID: 30092803 DOI: 10.1186/s12920-018-0383-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
46 Brandão M, Maurer C, Ziegelmann PK, Pondé NF, Ferreira A, Martel S, Piccart M, de Azambuja E, Debiasi M, Lambertini M. Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. ESMO Open 2020;5:e000842. [PMID: 32847835 DOI: 10.1136/esmoopen-2020-000842] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
47 Cragun D, Weidner A, Tezak A, Clouse K, Pal T. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Breast Cancer Res Treat 2020;182:421-8. [DOI: 10.1007/s10549-020-05699-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
48 Rosenthal SH, Sun W, Zhang K, Liu Y, Nguyen Q, Gerasimova A, Nery C, Cheng L, Castonguay C, Hiller E, Li J, Elzinga C, Wolfson D, Smolgovsky A, Chen R, Buller-Burckle A, Catanese J, Grupe A, Lacbawan F, Owen R. Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing. Biomed Res Int 2020;2020:3289023. [PMID: 32090079 DOI: 10.1155/2020/3289023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
49 Lynce F, Isaacs C. How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing. Am Soc Clin Oncol Educ Book 2016;35:e72-8. [PMID: 27249773 DOI: 10.1200/EDBK_160391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
50 Katsoulakis E, Duffy JE, Hintze B, Spector NL, Kelley MJ. Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program. JCO Precis Oncol 2020;4:PO. [PMID: 32923873 DOI: 10.1200/PO.19.00118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
51 Powers JM, Ebrahimzadeh JE, Katona BW. Genetic testing for hereditary gastrointestinal cancer syndromes: Interpreting results in today's practice. Curr Treat Options Gastroenterol 2019;17:636-49. [PMID: 31761969 DOI: 10.1007/s11938-019-00253-2] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Lu CY, Loomer S, Ceccarelli R, Mazor KM, Sabin J, Clayton EW, Ginsburg GS, Wu AC. Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer. J Pers Med 2018;8:E19. [PMID: 29772692 DOI: 10.3390/jpm8020019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
53 Everett JN, Mody RJ, Stoffel EM, Chinnaiyan AM. Incorporating genetic counseling into clinical care for children and adolescents with cancer. Future Oncol 2016;12:883-6. [PMID: 26888175 DOI: 10.2217/fon-2015-0022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
54 Katz SJ, Bondarenko I, Ward KC, Hamilton AS, Morrow M, Kurian AW, Hofer TP. Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. JAMA Surg 2018;153:909-16. [PMID: 29971344 DOI: 10.1001/jamasurg.2018.2001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
55 Underhill ML, Germansky KA, Yurgelun MB. Advances in Hereditary Colorectal and Pancreatic Cancers. Clin Ther 2016;38:1600-21. [PMID: 27045993 DOI: 10.1016/j.clinthera.2016.03.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
56 Kotnik U, Peterlin B, Lovrecic L. Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines. BMC Cancer 2021;21:665. [PMID: 34082720 DOI: 10.1186/s12885-021-08400-8] [Reference Citation Analysis]
57 Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist 2017;22:144-51. [PMID: 28179575 DOI: 10.1634/theoncologist.2016-0195] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
58 Maxwell KN, Hart SN, Vijai J, Schrader KA, Slavin TP, Thomas T, Wubbenhorst B, Ravichandran V, Moore RM, Hu C, Guidugli L, Wenz B, Domchek SM, Robson ME, Szabo C, Neuhausen SL, Weitzel JN, Offit K, Couch FJ, Nathanson KL. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. Am J Hum Genet 2016;98:801-17. [PMID: 27153395 DOI: 10.1016/j.ajhg.2016.02.024] [Cited by in Crossref: 79] [Cited by in F6Publishing: 62] [Article Influence: 19.8] [Reference Citation Analysis]
59 Tischkowitz M, Balmaña J, Foulkes WD, James P, Ngeow J, Schmutzler R, Voian N, Wick MJ, Stewart DR, Pal T; ACMG Professional Practice and Guidelines Committee. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021;23:1416-23. [PMID: 33976419 DOI: 10.1038/s41436-021-01151-8] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC. A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. Prostate 2016;76:1303-11. [PMID: 27324988 DOI: 10.1002/pros.23219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
61 Beri N, Patrick-Miller LJ, Egleston BL, Hall MJ, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS, Bradbury AR. Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clin Genet 2019;95:293-301. [PMID: 30417332 DOI: 10.1111/cge.13474] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
62 Hamilton JG, Long JM, Brandt AC, Brower J, Symecko H, Salo-Mullen EE, Christian SN, Harstad T, Couch FJ, Garber JE, Offit K, Robson ME, Domchek SM. Patients' Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing. JCO Precis Oncol 2019;3. [PMID: 31511843 DOI: 10.1200/PO.18.00300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
63 Hu Y, Alden RS, Odegaard JI, Fairclough SR, Chen R, Heng J, Feeney N, Nagy RJ, Shah J, Ulrich B, Gutierrez M, Lanman RB, Garber JE, Paweletz CP, Oxnard GR. Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 2017;23:7351-9. [PMID: 28947568 DOI: 10.1158/1078-0432.CCR-17-1745] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 10.8] [Reference Citation Analysis]
64 Bradbury AR. Implementation of Precision Cancer Medicine: Progress and the Path to Realizing the Promise of Tumor Sequencing. J Oncol Pract 2019;15:297-9. [PMID: 31112480 DOI: 10.1200/JOP.19.00176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Kinney AY, Howell R, Ruckman R, McDougall JA, Boyce TW, Vicuña B, Lee JH, Guest DD, Rycroft R, Valverde PA, Gallegos KM, Meisner A, Wiggins CL, Stroup A, Paddock LE, Walters ST. Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial. Contemp Clin Trials 2018;73:123-35. [PMID: 30236776 DOI: 10.1016/j.cct.2018.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Pipitprapat W, Pattanaprateep O, Iemwimangsa N, Sensorn I, Panthan B, Jiaranai P, Chantratita W, Sorapipatcharoen K, Poomthavorn P, Mahachoklertwattana P, Sura T, Tunteeratum A, Srichan K, Sriphrapradang C. Cost-minimization analysis of sequential genetic testing versus targeted next-generation sequencing gene panels in patients with pheochromocytoma and paraganglioma. Ann Med 2021;53:1243-55. [PMID: 34309460 DOI: 10.1080/07853890.2021.1956687] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Su TW, Zhong X, Ye L, Song W, Jiang L, Xie J, Jiang Y, Zhou W, Zhang C, Wu L, Ning G, Wang W. A nomogram for predicting the presence of germline mutations in pheochromocytomas and paragangliomas. Endocrine 2019;66:666-72. [PMID: 31606865 DOI: 10.1007/s12020-019-02075-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
68 Price KS, Svenson A, King E, Ready K, Lazarin GA. Inherited Cancer in the Age of Next-Generation Sequencing. Biol Res Nurs 2018;20:192-204. [PMID: 29325452 DOI: 10.1177/1099800417750746] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
69 Chun DS, Berse B, Venne VL, DuVall SL, Filipski KK, Kelley MJ, Meyer LJ, Icardi MS, Lynch JA. BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines. Fam Cancer 2017;16:41-9. [PMID: 27589855 DOI: 10.1007/s10689-016-9921-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
70 Jerzak KJ, Mancuso T, Eisen A. Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. Curr Oncol 2018;25:e176-80. [PMID: 29719442 DOI: 10.3747/co.25.3707] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 13.3] [Reference Citation Analysis]
71 Hung FH, Wang YA, Jian JW, Peng HP, Hsieh LL, Hung CF, Yang MM, Yang AS. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan. Sci Rep 2019;9:10229. [PMID: 31308460 DOI: 10.1038/s41598-019-46707-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Hamilton JG, Shuk E, Genoff MC, Rodríguez VM, Hay JL, Offit K, Robson ME. Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. J Oncol Pract 2017;13:e590-601. [PMID: 28628391 DOI: 10.1200/JOP.2016.020057] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
73 Pinheiro APM, Pocock RH, Switchenko JM, Dixon MD, Shaib WL, Ramalingam SS, Pentz RD. Discussing molecular testing in oncology care: Comparing patient and physician information preferences. Cancer 2017;123:1610-6. [PMID: 28140456 DOI: 10.1002/cncr.30494] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
74 Ginsburg O, Ashton-Prolla P, Cantor A, Mariosa D, Brennan P. The role of genomics in global cancer prevention. Nat Rev Clin Oncol 2021;18:116-28. [PMID: 32973296 DOI: 10.1038/s41571-020-0428-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
75 Pacyna JE, Radecki Breitkopf C, Jenkins SM, Sutton EJ, Horrow C, Kullo IJ, Sharp RR. Should pretest genetic counselling be required for patients pursuing genomic sequencing? Results from a survey of participants in a large genomic implementation study. J Med Genet 2019;56:317-24. [PMID: 30580287 DOI: 10.1136/jmedgenet-2018-105577] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
76 Katz SJ, Ward KC, Hamilton AS, Mcleod MC, Wallner LP, Morrow M, Jagsi R, Hawley ST, Kurian AW. Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol 2018;36:1218-24. [PMID: 29528794 DOI: 10.1200/JCO.2017.76.2369] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
77 Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Miller D, Penberthy LS, Katz SJ. Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. J Clin Oncol 2019;37:1305-15. [PMID: 30964716 DOI: 10.1200/JCO.18.01854] [Cited by in Crossref: 93] [Cited by in F6Publishing: 42] [Article Influence: 46.5] [Reference Citation Analysis]
78 Stradella A, Del Valle J, Rofes P, Feliubadaló L, Grau Garces È, Velasco À, González S, Vargas G, Izquierdo Á, Campos O, Tornero E, Navarro M, Balmaña-Gelpi J, Capellá G, Pineda M, Brunet J, Lázaro C. Does multilocus inherited neoplasia alleles syndrome have severe clinical expression? J Med Genet 2019;56:521-5. [PMID: 30580288 DOI: 10.1136/jmedgenet-2018-105700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
79 Arango NP, Brusco L, Mills Shaw KR, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 2017;8:41806-14. [PMID: 28415679 DOI: 10.18632/oncotarget.16018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
80 You YN, Lee LD, Deschner BW, Shibata D. Colorectal Cancer in the Adolescent and Young Adult Population. JCO Oncol Pract 2020;16:19-27. [PMID: 32039664 DOI: 10.1200/JOP.19.00153] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Peterson EB, Chou WS, Gaysynsky A, Krakow M, Elrick A, Khoury MJ, Kaphingst KA. Communication of cancer-related genetic and genomic information: A landscape analysis of reviews. Transl Behav Med 2018;8:59-70. [PMID: 29385592 DOI: 10.1093/tbm/ibx063] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
82 Wang D, Liang S, Zhang X, Dey SK, Li Y, Xu C, Yu Y, Li M, Zhao G, Zhang Z. Targeted next-generation sequencing approach for molecular genetic diagnosis of hereditary colorectal cancer: Identification of a novel single nucleotide germline insertion in adenomatous polyposis coli gene causes familial adenomatous polyposis. Mol Genet Genomic Med 2019;7:e00505. [PMID: 30523670 DOI: 10.1002/mgg3.505] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
83 Courtney E, Li ST, Shaw T, Chen Y, Allen JC Jr, Ngeow J. Predictors of next-generation sequencing panel selection using a shared decision-making approach. NPJ Genom Med 2018;3:11. [PMID: 29736259 DOI: 10.1038/s41525-018-0050-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
84 Solano AR, Cardoso FC, Romano V, Perazzo F, Bas C, Recondo G, Santillan FB, Gonzalez E, Abalo E, Viniegra M, Michel JD, Nuñez LM, Noblia CM, Mc Lean I, Canton ED, Chacon RD, Cortese G, Varela EB, Greco M, Barrientos ML, Avila SA, Vuotto HD, Lorusso A, Podesta EJ, Mando OG. Spectrum of BRCA1/2 variants in 940 patients from Argentina including novel, deleterious and recurrent germline mutations: impact on healthcare and clinical practice. Oncotarget 2017;8:60487-95. [PMID: 28947987 DOI: 10.18632/oncotarget.10814] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
85 Hoxhaj I, Tognetto A, Acampora A, Stojanovic J, Boccia S. Core Competencies in Cancer Genomics for Healthcare Professionals: Results From a Systematic Literature Review and a Delphi Process. J Cancer Educ 2021. [PMID: 33442861 DOI: 10.1007/s13187-021-01956-w] [Reference Citation Analysis]
86 Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer 2020;126:549-58. [PMID: 31682005 DOI: 10.1002/cncr.32572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
87 Agnese DM, Pollock RE. Breast Cancer Genetic Counseling: A Surgeon's Perspective. Front Surg 2016;3:4. [PMID: 26858951 DOI: 10.3389/fsurg.2016.00004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
88 Freitas AC, Opinião A, Fragoso S, Nunes H, Santos M, Clara A, Bento S, Luis A, Silva J, Moura C, Filipe B, Machado P, Santos S, André S, Rodrigues P, Parreira J, Vaz F. Men seeking counselling in a Breast Cancer Risk Evaluation Clinic. Ecancermedicalscience 2018;12:804. [PMID: 29456621 DOI: 10.3332/ecancer.2018.804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
89 Bylstra Y, Lysaght T, Thrivikraman J, Watson S, Tan P. Ethical frameworks for obtaining informed consent in tumour profiling: an evidence-based case for Singapore. Hum Genomics 2017;11:31. [PMID: 29221462 DOI: 10.1186/s40246-017-0127-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
90 Giri VN, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty SE, Montgomery S, Forman A, Bingler R, Kelly WK, Dicker AP, Winheld S, Trabulsi EJ, Chen DYT, Lallas CD, Allen BA, Daly MB, Gomella LG. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precis Oncol 2017;1:PO. [PMID: 34164591 DOI: 10.1200/PO.16.00039] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
91 Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol 2020;38:2798-811. [PMID: 32516092 DOI: 10.1200/JCO.20.00046] [Cited by in Crossref: 56] [Cited by in F6Publishing: 24] [Article Influence: 56.0] [Reference Citation Analysis]
92 McCarthy AM, Bristol M, Domchek SM, Groeneveld PW, Kim Y, Motanya UN, Shea JA, Armstrong K. Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer. J Clin Oncol 2016;34:2610-8. [PMID: 27161971 DOI: 10.1200/JCO.2015.66.0019] [Cited by in Crossref: 74] [Cited by in F6Publishing: 33] [Article Influence: 14.8] [Reference Citation Analysis]
93 Reid S, Pal T. Update on multi-gene panel testing and communication of genetic test results. Breast J 2020;26:1513-9. [PMID: 32639074 DOI: 10.1111/tbj.13971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019;11:102-16. [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
95 Heald B, Hampel H, Church J, Dudley B, Hall MJ, Mork ME, Singh A, Stoffel E, Stoll J, You YN, Yurgelun MB, Kupfer SS; Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Fam Cancer 2020;19:223-39. [PMID: 32172433 DOI: 10.1007/s10689-020-00170-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
96 Bradbury AR, Patrick-Miller L, Egleston BL, Maxwell KN, DiGiovanni L, Brower J, Fetzer D, Bennett Gaieski J, Brandt A, McKenna D, Long J, Powers J, Stopfer JE, Nathanson KL, Domchek SM. Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. JCO Precis Oncol 2018;2. [PMID: 32095738 DOI: 10.1200/po.17.00250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
97 Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin Genitourin Cancer 2019;17:275-282.e1. [PMID: 31171481 DOI: 10.1016/j.clgc.2019.04.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
98 Pócza T, Grolmusz VK, Papp J, Butz H, Patócs A, Bozsik A. Germline Structural Variations in Cancer Predisposition Genes. Front Genet 2021;12:634217. [PMID: 33936164 DOI: 10.3389/fgene.2021.634217] [Reference Citation Analysis]
99 Gray SW, Park ER, Najita J, Martins Y, Traeger L, Bair E, Gagne J, Garber J, Jänne PA, Lindeman N, Lowenstein C, Oliver N, Sholl L, Van Allen EM, Wagle N, Wood S, Garraway L, Joffe S. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med 2016;18:1011-9. [PMID: 26866579 DOI: 10.1038/gim.2015.207] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 15.6] [Reference Citation Analysis]
100 Benusiglio PR, Di Maria M, Dorling L, Jouinot A, Poli A, Villebasse S, Le Mentec M, Claret B, Boinon D, Caron O. Hereditary breast and ovarian cancer: successful systematic implementation of a group approach to genetic counselling. Fam Cancer 2017;16:51-6. [PMID: 27624814 DOI: 10.1007/s10689-016-9929-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
101 Butz H, Blair J, Patócs A. Molecular genetic testing strategies used in diagnostic flow for hereditary endocrine tumour syndromes. Endocrine 2021;71:641-52. [PMID: 33570725 DOI: 10.1007/s12020-021-02636-x] [Reference Citation Analysis]
102 Wakai T, Prasoon P, Hirose Y, Shimada Y, Ichikawa H, Nagahashi M. Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors. Int J Clin Oncol 2019;24:115-22. [PMID: 30515675 DOI: 10.1007/s10147-018-1375-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
103 Waaijer L, Filipe MD, Simons J, van der Pol CC, de Boorder T, van Diest PJ, Witkamp AJ. Detection of breast cancer precursor lesions by autofluorescence ductoscopy. Breast Cancer 2021;28:119-29. [PMID: 32725533 DOI: 10.1007/s12282-020-01136-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
104 Buchanan AH, Rahm AK, Williams JL. Alternate Service Delivery Models in Cancer Genetic Counseling: A Mini-Review. Front Oncol 2016;6:120. [PMID: 27242960 DOI: 10.3389/fonc.2016.00120] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 12.0] [Reference Citation Analysis]
105 Cragun D, Scherr C, Camperlengo L, Vadaparampil ST, Pal T. Evolution of Hereditary Breast Cancer Genetic Services: Are Changes Reflected in the Knowledge and Clinical Practices of Florida Providers? Genet Test Mol Biomarkers 2016;20:569-78. [PMID: 27525501 DOI: 10.1089/gtmb.2016.0113] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
106 Jain RK, Chen H. Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib. Lung Cancer (Auckl) 2017;8:169-77. [PMID: 29075144 DOI: 10.2147/LCTT.S126507] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
107 Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol 2017;9:519-31. [PMID: 28794804 DOI: 10.1177/1758834017714993] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
108 Maitra D, Manek P, Gupta N, Srivastava A. Genetic Counseling Clinic at AIIMS (New Delhi). Indian J Surg Oncol 2021;12:30-3. [PMID: 33994725 DOI: 10.1007/s13193-020-01054-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Niu X, Amendola LM, Hart R, Bennette CS, Heagerty P, Horike-Pyne M, Trinidad SB, Rosenthal EA, Comstock B, Nefcy C, Hisama FM, Bennett RL, Grady WM, Gallego CJ, Tarczy-Hornoch P, Fullerton SM, Burke W, Regier DA, Dorschner MO, Shirts BH, Robertson PD, Nickerson DA, Patrick DL, Jarvik GP, Veenstra DL. Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study. Contemp Clin Trials 2019;84:105820. [PMID: 31400517 DOI: 10.1016/j.cct.2019.105820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
110 Ngeow J, Eng C. Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet. NPJ Genom Med 2016;1:15006. [PMID: 29263804 DOI: 10.1038/npjgenmed.2015.6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
111 Lobo M, López-Tarruella S, Luque S, Lizarraga S, Flores-Sánchez C, Bueno O, Solera J, Jerez Y, Del Val RG, Palomero MI, Cebollero M, Echavarría I, Torres G, Martín M, Márquez-Rodas I. Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. J Genet Couns 2018;27:854-62. [PMID: 29247312 DOI: 10.1007/s10897-017-0187-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
112 Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, Penault-Llorca F. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open 2019;4:e000442. [PMID: 30792906 DOI: 10.1136/esmoopen-2018-000442] [Cited by in Crossref: 109] [Cited by in F6Publishing: 88] [Article Influence: 54.5] [Reference Citation Analysis]
113 Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol 2019;3. [PMID: 31517177 DOI: 10.1200/PO.18.00143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
114 Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer 2019;18:241-51. [PMID: 30267352 DOI: 10.1007/s10689-018-0106-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
115 Stoffel EM, Koeppe E, Everett J, Ulintz P, Kiel M, Osborne J, Williams L, Hanson K, Gruber SB, Rozek LS. Germline Genetic Features of Young Individuals With Colorectal Cancer. Gastroenterology. 2018;154:897-905.e1. [PMID: 29146522 DOI: 10.1053/j.gastro.2017.11.004] [Cited by in Crossref: 97] [Cited by in F6Publishing: 88] [Article Influence: 24.3] [Reference Citation Analysis]
116 You YN, Borras E, Chang K, Price BA, Mork M, Chang GJ, Rodriguez-Bigas MA, Bednarski BK, Meric-Bernstam F, Vilar E. Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine. Dis Colon Rectum 2019;62:429-37. [PMID: 30730459 DOI: 10.1097/DCR.0000000000001322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
117 Seifert BA, McGlaughon JL, Jackson SA, Ritter DI, Roberts ME, Schmidt RJ, Thompson BA, Jimenez S, Trapp M, Lee K, Plon SE, Offit K, Stadler ZK, Zhang L, Greenblatt MS, Ferber MJ. Determining the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the Clinical Genome Resource Clinical Validity Framework. Genet Med. 2019;21:1507-1516. [PMID: 30523343 DOI: 10.1038/s41436-018-0373-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
118 Blazer KR, Slavin T, Weitzel JN. Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer. JAMA Oncol 2016;2:723-4. [PMID: 26869327 DOI: 10.1001/jamaoncol.2015.5975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
119 Weipert CM, Ryan KA, Everett JN, Yashar BM, Chinnaiyan AM, Scott Roberts J, De Vries R, Zikmund-Fisher BJ, Raymond VM. Physician Experiences and Understanding of Genomic Sequencing in Oncology. J Genet Couns 2018;27:187-96. [PMID: 28840409 DOI: 10.1007/s10897-017-0134-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
120 Jordan F, Huber S, Sommer S, Schenkirsch G, Frühwald MC, Trepel M, Claus R, Kuhlen M. A Retrospective 5-Year Single Center Study Highlighting the Risk of Cancer Predisposition in Adolescents and Young Adults. Cancers (Basel) 2021;13:3033. [PMID: 34204522 DOI: 10.3390/cancers13123033] [Reference Citation Analysis]
121 Ginsburg O, Narod SA. Clinical Cancer Genetics in a Lower-Middle Income Country: Considerations for Policymaking. J Glob Oncol 2018;4:1-3. [PMID: 30084717 DOI: 10.1200/JGO.18.00081] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Lincoln SE, Nussbaum RL, Kurian AW, Nielsen SM, Das K, Michalski S, Yang S, Ngo N, Blanco A, Esplin ED. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. JAMA Netw Open 2020;3:e2019452. [PMID: 33026450 DOI: 10.1001/jamanetworkopen.2020.19452] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 13.0] [Reference Citation Analysis]
123 Malhotra H, Kowtal P, Mehra N, Pramank R, Sarin R, Rajkumar T, Gupta S, Bapna A, Bhattacharyya GS, Gupta S, Maheshwari A, Mannan AU, Reddy Kundur R, Sekhon R, Singhal M, Smruti BK, Sp S, Suryavanshi M, Verma A. Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology. JCO Glob Oncol 2020;6:991-1008. [PMID: 32628584 DOI: 10.1200/JGO.19.00381] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]